HARP News and Press, Harpoon Therapeutics Inc. From 05/02/22

Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and clinical-stage biotech, Harpoon Therapeutics (NASDAQ:HARP) have entered into a clinical supply agreement for the delivery of Roche’s (OTCQX:RHHBY) cancer therapy atezolizumab (Tecentriq) in studies that Harpoon (HARP) expects to ...

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to sup...

Gainers: Avadel Pharmaceuticals  (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment  (RDBX) +6%. CymaBay Therapeutics  (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Associ...

The clinical-stage immunotherapy company, Harpoon Therapeutics (NASDAQ:HARP) is trading ~4% lower in the post-market Thursday after announcing the departure of its Chief Medical Officer, Natalie Sacks, effective June 01, 2022. However, Dr. Sacks will serve the company as a consultan...

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, ...

Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week high today of $25.05. Approximately 10.9 million shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Over the past year, Harpoon Therapeutics Inc. has traded in a range of $3.30 to $24...

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncolo...

Several Street firms have lowered their price targets for Harpoon Therapeutics (HARP -10.9%) though are keeping either buy or overweight ratings. Shares are down 11% in late morning trading. Piper Sandler's Joseph Catanzaro lowered his target to $15 from $27 (~282% return based on F...

The clinical-stage immunotherapy company Harpoon Therapeutics (HARP -34.8%) have lost more than a third on Friday after announcing its plans to discontinue the clinical work on HPN424, an experimental therapy for prostate cancer. The decision followed “a careful and thorough analysis o...